Drug intelligence / Profile preview

dexmedetomidine + nefopam

Development stage
Preclinical
Lead developer
Orion Pharma
Modality
Small Molecules
Administration
Intravenous
01

Overview

Dexmedetomidine + nefopam is a combination of two centrally acting, non-opioid analgesic agents used primarily for perioperative and postoperative pain management. Dexmedetomidine is a highly selective α2-adrenergic receptor agonist that provides sedation, anxiolysis, and analgesia without significant respiratory depression. Nefopam is a non-opioid, non-steroidal analgesic that inhibits the reuptake of serotonin, norepinephrine, and dopamine in the central nervous system and also has NMDA receptor antagonist activity. The combination aims to provide enhanced multimodal analgesia with opioid-sparing effects and improved pain control after surgery[1][2][5]. Both drugs are used as part of multimodal regimens to reduce opioid consumption and their associated side effects.

02

Targets

ADRA2B (α2B)NaV (Voltage-gated sodium channels)ADRA2A (α2A)SERT (Sodium-dependent serotonin transporter)ADRA2C (α2C)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on dexmedetomidine + nefopam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexmedetomidine + nefopam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call